



## March 12, 2025 (Toulouse - France)

### PRELIMINARY PROGRAM

- 8:00 a.m. Welcome coffee and networking
- 8:45 – 9:00 a.m. **Introduction:** *Luigi Ferrucci*<sup>1</sup> *Roger Fielding*<sup>2</sup> *Bruno Vellas*<sup>3</sup> *John Newman*<sup>4</sup>
1. National Institute on Aging (*Baltimore, MD – USA*)
  2. Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (*Boston, MA – USA*)
  3. IHU HealthAge (*Toulouse, France*)
  4. Buck Institute (*Novato, CA – USA*)
- 9:00 – 9:15 a.m. **Geroscience pre-clinical and clinical trials where we are and where we must go**  
*Luigi Ferrucci* - National Institute on Aging (*Baltimore, MD – USA*)
- 9:15 – 9:30 a.m. **Reconciling the harmful versus beneficial roles of cellular senescence and the role of senolytics in multimorbidity**  
*George Kuchel* - Uconn Health (*Farmington, CT – USA*)
- 9:30 – 9:45 a.m. **Blood-Based Protein Biomarkers of Longevity – A Path to Implementation in Clinical Trials**  
*Amos Baruch* - Calico Life Sciences (*South San Francisco, CA – USA*)
- 9:45 – 10:00 a.m. **Discussion**
- Randomized Controlled Trials in Geroscience**  
Chair: *Felipe Sierra* - Hevolution Foundation (*Boston, MA – USA*)
- 10:00 – 10:15 a.m. **RCTs of NAD augmentation**  
*Shalender Bhasin* - Brigham and Women's Hospital (*Boston, MA - USA*)
- 10:15 – 10:30 a.m. **Launching TAKEOFF: Pilot data on a ketone ester informing a multicenter RCT**  
*John Newman* - Buck Institute (*Novato, CA – USA*)
- 10.30 – 10.45 a.m. **Moving from basic research to RCT**  
*Nathan LeBrasseur* - Mayo Clinic (*Rochester, Minnesota – USA*)
- 10:45 – 11:00 a.m. **Discussion**

### Pre-Clinical and Clinical Trials in Geroscience: Short communications

Co-Chairs: *Jean-Yves Reginster*, College of Science, King Saud University (*Riyadh, Saudi Arabia*) and *Bruno Vellas*, IHU HealthAge, Toulouse (France)

- 11:00 – 11:10 a.m. **Geroscience guided rapamycin clinical trials: Rationale and experimental design**  
*Adam Konopka* - University of Wisconsin-Madison (*Madison, WI – USA*)
- 11:10 – 11:20 a.m. **Role of cell therapy in osteoarthritis**  
*Ali Mobasheri*<sup>1</sup>, *Jean-Yves Reginster*<sup>2</sup>  
1. Faculty of Medicine, University of Oulu (*Oulu, Finland*)  
2. College of Science, King Saud University (*Riyadh, Saudi Arabia*)
- 11:20 – 11:30 a.m. **Identifying and targeting pathological senescent articular cells to delay joint degeneration in age-related osteoarthritis**  
*Jean-Marc Brondello* - IRMB Montpellier University and INSERM UMR1183. (*Montpellier, France*)
- 11:30 – 11:40 a.m. **Late-onset exercise training intervention promotes a healthy aging signature in skeletal muscle by improving mitochondrial health and functional status**  
*Maria Carmen Gomez-Cabrera* - University of Valencia, INCLIVA (*Valencia, Spain*)
- 11:40 – 11:50 a.m. **Inorganic polyphosphate and dietary restriction: interactions between physiology and age-related pathology**  
*Luca Tagliafico* - University of Genoa and IRCCS Ospedale Policlinico San Martino (*Genoa, Italy*)
- 11:50 – 12:00 p.m. **Leveraging Geroscience to Target Novel Mechanisms in Genitourinary Disease: The Prescription exercise for Older men with Urinary Disease (PROUD) Trial**  
*Scott Bauer* - University of California San Francisco (*San Francisco, CA - USA*)
- 12:00 – 12:15 p.m. **Discussion**

12.15 – 1.00 p.m. **Lunch**

### Pre-Clinical and Clinical Trials in Geroscience: Short communications

Co-Chairs: *Roger Fielding*, Tufts University (Boston, MA – USA) and *Yves Rolland*, IHU HealthAge (Toulouse, France)

- 1:00 – 1:10 p.m. **Sex dependent senotherapeutic effects is predicted by visceral adipose tissue response in aging and Alzheimer's models**  
*Kevin N. Hascup* - Southern Illinois University School of Medicine (*Springfield, IL – USA*)

- 1:10 – 1:20 p.m. **ICOPE + Geroscience Proof of Concept Trial**  
*Yves Rolland - IHU HealthAge (Toulouse, France)*
- 1:20 – 1:30 p.m. **Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial**  
*Heike Bischoff-Ferrari - University Department of Aging Medicine Felix Platter (Basel, Switzerland)*
- 1:30 – 1:40 p.m. **The effects of therapeutic plasma exchange (plasmapheresis) on age-related biomarkers: a double-blind, placebo-controlled clinical trials**  
*Dobri Kiproff - Global Apheresis (Mill Valley, CA – USA)*
- 1:40 – 2:00 p.m. General discussion**

**Pre-Clinical and Clinical Trials in Geroscience: Short communications**

Co-Chairs: *John Newman*, Buck Institute (Novato, CA – USA) and *Philippe Barreto*, IHU HealthAge (Toulouse, France)

- 2:00 – 2:10 p.m. **Mapping the Responsiveness of 100+ Epigenetic Biomarkers Across 50+ Anti-Aging Interventions in Human Clinical Trials**  
*Raghav Sehgal - Yale University (New Haven, CT – USA)*
- 2:10 – 2:20 p.m. **Omics Aging Biomarkers for Clinical Trials using the TransLAGE Knowledgebase**  
*Albert Higgins-Chen - Yale University (New Haven, CT – USA)*
- 2:20 – 2:30 p.m. **Novel Gerotherapeutic Peptide PTC-2105 Reverses the Aging Phenotype In Naturally Aged Mice**  
*Kevin Slawin - Eos Senolytix, Inc. (Surfside, FL – USA)*
- 2:30 – 2:40 p.m. **Context-dependent role of senescent cells, senescence heterogeneity, and the effect of senolytics**  
*Raghavan Pillai Raju - Medical College of Georgia (Augusta, GA – USA)*
- 2:40 – 2:50 p.m. **Effect of a Multifactorial Weight Loss Intervention on HDL Cholesterol Efflux Capacity and Immunosenescence: A Randomized Controlled Trial**  
*Lidia Daimiel - Fundacion IMDEA Alimentacion (Madrid, Spain)*
- 2:50 – 3:10 p.m. General discussion**
- 3:30 p.m. ICFSR Conference Opening**